Ocugen has entered into a licensing agreement with Roots Pharmaceutical for the rights to OCU400 in the Middle East and North Africa. This deal includes potential sales milestones up to $255 million and 22% royalties on net sales, with Ocugen retaining manufacturing responsibilities.
Ocugen has announced a licensing agreement with Roots Pharmaceutical for its gene therapy OCU400, targeting Retinitis Pigmentosa, specifically for the Middle East and North Africa (MENA) region. This is a positive development for Ocugen as it expands the potential market reach for OCU400 and introduces new revenue streams through upfront/near-term development milestones, cumulative sales milestones up to $255 million, and 22% royalties on net sales. While the upfront payment amount is not disclosed, the potential for significant milestone payments and ongoing royalties provides a long-term financial benefit. Ocugen will also retain the manufacturing and supply responsibilities, ensuring continued involvement and control over the product. This agreement helps de-risk the commercialization of OCU400 in a new geographic area and could be a precursor to similar deals in other regions, offering a positive signal for investors regarding the company's strategic execution and the value of its pipeline.